当前位置: X-MOL 学术Leukemia › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group
Leukemia ( IF 12.8 ) Pub Date : 2017-09-15 , DOI: 10.1038/leu.2017.246
M A Hoechstetter , R Busch , B Eichhorst , A Bühler , D Winkler , M J Eckart , U Vehling-Kaiser , H Schimke , U Jäger , H J Hurtz , G Hopfinger , F Hartmann , H Fuss , W Abenhardt , I Blau , W Freier , L Müller , M Goebeler , C M Wendtner , J Bahlo , K Fischer , M Bentz , B Emmerich , H Döhner , M Hallek , S Stilgenbauer

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

Leukemia advance online publication, September 15 2017. doi:10.1038/leu.2017.246

Authors: M A Hoechstetter, R Busch, B Eichhorst, A Bühler, D Winkler, M J Eckart, U Vehling-Kaiser, H Schimke, U Jäger, H J Hurtz, G Hopfinger, F Hartmann, H Fuss, W Abenhardt, I Blau, W Freier, L Müller, M Goebeler, C M Wendtner, J Bahlo, K Fischer, M Bentz, B Emmerich, H Döhner, M Hallek & S Stilgenbauer



中文翻译:

在Binet A期慢性淋巴细胞白血病患者中进行氟达拉滨的早期风险适应性治疗:德国CLL研究组的CLL1试验结果

在Binet A期慢性淋巴细胞白血病患者中进行氟达拉滨的早期风险适应性治疗:德国CLL研究组的CLL1试验结果

白血病提前在线发布,2017年9月15日 。doi:10.1038 / leu.2017.246

作者:MA Hoechstetter,R Busch,B Eichhorst,ABühler,D Winkler,MJ Eckart,U Vehling-Kaiser,H Schimke,UJäger,HJ Hurtz,G Hopfinger,F Hartmann,H Fuss,W Abenhardt,I Blau,W弗赖尔,穆勒(L.

更新日期:2017-09-16
down
wechat
bug